Dyadic International Progresses Multiple Protein Production Partnerships
MT Newswires Live
Jul 07
Dyadic International (DYAI) achieved multiple development milestones in its global health partnerships using its C1 protein production platform, the company said Tuesday.
Researchers completed a production phase from plasmid to purified protein in roughly 15 days under a joint project with international health foundations, the company said.
The company expects to send refined viral samples to Scripps Research for vaccine studies by the end of July, Dyadic International said.
Shares of the company were up 2.9% early Tuesday.
Price: 1.00, Change: +0.03, Percent Change: +2.88
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.